Core Insights - Guggenheim maintains a "Buy" rating for MBX Biosciences, raising the price target from $44 to $84, while the stock was priced at $10 at the time of the report [1][5] - MBX's treatment, Canvuparatide, has shown promising results in clinical trials, achieving a 63% responder rate at 12 weeks and a 79% rate at 6 months [2][5] - The stock price of MBX has surged by 105.05%, currently priced at $20.51, reflecting strong investor confidence [3][5] Company Performance - MBX's market capitalization is approximately $688.84 million, with a trading volume of 19,500,369 shares [4] - The company is preparing for a Phase 3 trial in 2026, which is a key factor contributing to its market position [4] - The stock has fluctuated between $20 and $26.45, with a 52-week high of $27.50 and a low of $4.81 [3]

Company Acquisitions - Pfizer Inc. has agreed to acquire Metsera, Inc. to enhance its portfolio in medicines targeting obesity and cardiometabolic diseases, introducing a range of oral and injectable therapy candidates [2] Stock Market Performance - U.S. stocks showed a mostly positive trend, with the Nasdaq Composite gaining over 50 points, while the Dow increased by 0.01% to 46,321.12, and the S&P 500 rose by 0.15% to 6,674.60 [1] - Information technology shares increased by 0.4%, while consumer staples stocks fell by 0.5% [1] Commodity Market - Oil prices decreased by 0.7% to $62.23, while gold prices increased by 1.3% to $3,752.30. Silver rose by 2.1% to $43.835, and copper fell by 0.4% to $4.6085 [5] Stock Movements - AgriFORCE Growing Systems Ltd. saw a significant increase of 157% to $6.20 following its announcement to rename and raise approximately $550 million [9] - Qualigen Therapeutics, Inc. surged by 141% to $6.86 after a $41 million investment from Faraday Future [9] - MBX Biosciences, Inc. rose by 134% to $23.43 after positive Phase 2 trial results for Canvuparatide [9] - Chijet Motor Company, Inc. shares dropped by 38% to $0.1813 after naming a new COO [9] - Cosan S.A. shares fell by 23% to $4.3850 following a downgrade from HSBC [9] - Quantum Computing Inc. decreased by 14% to $19.97 after announcing a $500 million oversubscribed private placement [9]

Phase 2 Trial and Open-Label Extension Top-Line Results: Once-Weekly Canvuparatide in Adults with Hypoparathyroidism September 22, 2025 Disclaimer This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our product candidates, preclinical study and/or clinical trial timelines, including projected data announcements, future results of operations and financial position, strategy and plans, in ...

Core Insights - Several clinical-stage biotech companies experienced significant after-hours trading momentum due to anticipated trial data releases and pipeline updates [1] Company Summaries - **MBX Biosciences Inc. (MBX)**: Shares surged 33% in after-hours trading, rising from $10.00 to $13.77, following the announcement of topline results from its Phase 2 trial of Canvuparatide, expected on September 22 [2][3] - **Structure Therapeutics Inc. (GPCR)**: Stock increased 11.37% to $26.26 after closing at $23.58, driven by interest in its lead candidate aleniglipron, with topline results from two Phase 2b trials expected by the end of 2025 [4] - **Cartesian Therapeutics Inc. (RNAC)**: Shares rose 5.51% to $9.96 after a decline during the day, with preliminary data from the Phase 2 trial of Descartes-08 expected in the second half of 2025 [5][6] - **Rapport Therapeutics Inc. (RAPP)**: Stock increased 3.60% to $27.31, following positive topline results from its Phase 2a trial for RAP-219, with Phase 3 trials expected to start in 2026 [9][10] - **Rezolute Inc. (RZLT)**: Shares rose 3.77% to $7.99 after a decline during the day, with topline data from the Phase 3 sunRIZE trial for congenital hyperinsulinism expected in December 2025 [11][12]